Cyclooxygenase-2 inhibitor induces apoptosis and enhances cytotoxicity of various anticancer agents in non-small cell lung cancer cell lines

Clinical Cancer Research

Volumn 6, Issue 5, 2000, Pages 2006-2011

  Hida, Toyoaki ^a   Kozaki, Ken Ichi ^a   Muramatsu, Hideki ^b   Masuda, Akira ^a   Shimizu, Shigeki ^b   Mitsudomi, Tetsuya ^b   Sugiura, Takahiko ^b   Ogawa, Makoto ^b   Takahashi, Takashi ^a  

^a AICHI CANCER CENTER HOSPITAL   (Japan)

^b NONE

Author keywords

[No Author keywords available]

Indexed keywords

AMRUBICIN; ANTINEOPLASTIC AGENT; CYCLOOXYGENASE 2 INHIBITOR; DOCETAXEL; ETOPOSIDE; IRINOTECAN; NIMESULIDE;

APOPTOSIS; ARTICLE; CELL PROLIFERATION; CYTOTOXICITY; DRUG EFFICACY; DRUG MECHANISM; ENZYME INHIBITION; HIGH RISK POPULATION; HUMAN; HUMAN CELL; LUNG NON SMALL CELL CANCER; PRIORITY JOURNAL; PROTEIN EXPRESSION; QUALITY OF LIFE;

ANTINEOPLASTIC AGENTS; APOPTOSIS; CARCINOMA, NON-SMALL-CELL LUNG; CELL SURVIVAL; CYCLOOXYGENASE 2; CYCLOOXYGENASE 2 INHIBITORS; CYCLOOXYGENASE INHIBITORS; DOSE-RESPONSE RELATIONSHIP, DRUG; DRUG SYNERGISM; GENE EXPRESSION REGULATION, NEOPLASTIC; HUMANS; ISOENZYMES; LUNG NEOPLASMS; MEMBRANE PROTEINS; PROSTAGLANDIN-ENDOPEROXIDE SYNTHASES; RNA, NEOPLASM; SULFONAMIDES; TUMOR CELLS, CULTURED; TUMOR SUPPRESSOR PROTEIN P53;

EID: 0034026144     PISSN: 10780432     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Article

References (31)

1. Nesbitt, J. C., Lee, J. S., Komaki, R., and Roth, J. A. Cancer of the lung. In: J. F. Holland, R. C. Bast, Jr., D. L. Morton, E. Frei III, D. W. Kufe, and R. R. Weichselbaum (eds.), Cancer Medicine, Ed. 4, pp. 1723-1795. Baltimore: Williams and Wilkins, 1997.
2. Rigas, J. R. Do newer chemotherapeutic agents improve survival in non-small cell lung cancer? Semin. Oncol., 25: 5-9, 1998.
3. Williams, C. S., Smalley, W., and DuBois, R. N. Aspirin use and potential mechanisms for colorectal cancer prevention. J. Clin. Invest., 100: 1325-1329, 1997.
4. Taketo, M. M. Cyclooxygenase-2 inhibitors in tumorigenesis (part I). J. Natl. Cancer Inst., 90: 1529-1536, 1998.
5. Taketo, M. M. Cyclooxygenase-2 inhibitors in tumorigenesis (part II). J. Natl. Cancer Inst., 90: 1609-1620, 1998.
6. Pepin, P., Bouchard, L., Nicole, P., and Castonguay, A. Effects of sulindac and oltipraz on the tumorigenicity of 4-(methylnitrosamino)1-(3-pyridyl)-1-butanone in A/J mouse lung. Carcinogenesis (Lond.)., 13: 341-348, 1992.
7. Malkinson, A. M., Koski, K. M., Dwyer-Nield, L. D., Rice, P. L., Rioux, N., Castonguay, A., Ahnen, D. J., Thompson, H., Pamukcu, R., and Piazza, G. A. Inhibition of 4-(methylnitrosamino)-1-(3-pyridyl)-1-butanone-induced mouse lung tumor formation by FGN-1 (sulindac sulfone). Carcinogenesis (Lond.)., 19: 1353-1356, 1998.
8. Castonguay, A., and Rioux, N. Inhibition of lung tumourigenesis by sulindac: comparison of two experimental protocols. Carcinogenesis (Lond.)., 18: 491-496, 1997.
9. Hida, T., Yatabe, Y., Achiwa, H., Muramatsu, H., Kozaki, K., Nakamura, S., Ogawa, M., Mitsudomi, T., Sugiura, T., and Takahashi, T. Increased expression of cyclooxygenase 2 occurs frequently in human lung cancers, specifically in adenocarcinomas. Cancer Res., 58: 3761-3764, 1998.
10. Achiwa, H., Yatabe, Y., Hida, T., Kuroishi, T., Kozaki, K., Nakamura, S., Ogawa, M., Sugiura, T., Mitsudomi, T., and Takahashi, T. Prognostic significance of elevated cyclooxygenase 2 expression in primary, resected lung adenocarcinomas. Clin. Cancer Res., 5: 1001-1005, 1999.
11. Vane, J. Towards a better aspirin. Nature (Lond.)., 367: 215-216, 1994.
12. Famaey, J. P. In vitro and in vivo pharmacological evidence of selective cyclooxygenase-2 inhibition by nimesulide: an overview. Inflamm. Res., 46: 437-446, 1997.
13. Davis, R., and Brogden, R. N. Nimesulide. An update of its pharmacodynamic and pharmacokinetic properties, and therapeutic efficacy. Drugs, 48: 431-454, 1994.
14. Hida, T., Ariyoshi, Y., Kuwabara, M., Sugiura, T., Takahashi, T., Takahashi, T., Hosoda, K., Niitsu, Y., and Ueda, R. Glutathione S-transferase pi levels in a panel of lung cancer cell lines and its relation to cherno-radiosensitivity. Jpn. J. Clin. Oncol., 23: 14-19, 1993.
15. Masuda, A., Kondo, M., Saito, T., Yatabe, Y., Kobayashi, T., Okamoto, M., Suyama, M., and Takahashi, T. Establishment of human peripheral lung epithelial cell lines (HPL1) retaining differentiated characteristics and responsiveness to epidermal growth factor, hepatocyte growth factor, and transforming growth factor β1. Cancer Res., 57: 4898-4904, 1997.
16. Reddel, R. R., Ke, Y., Gerwin, B. I., McMenamin, M. G., Lechner, J. F., Su, R. T., Brash, D. E., Park, J. B., Rhim, J. S., and Harris, C. C. Transformation of human bronchial epithelial cells by infection with SV40 or adenovirus-12 SV40 hybrid virus, or transfection via strontium phosphate coprecipitation with a plasmid containing SV40 early region genes. Cancer Res., 48: 1904-1909, 1988.
17. Hida, T., Ueda, R., Takahashi, T., Watanabe, H., Kato, T., Suyama, M., Sugiura, T., Ariyoshi, Y., and Takahashi. T. Chemosensitivity and radiosensitivity of small cell lung cancer cell lines studied by a newly developed 3-(4,5-dimethylthiazol-2-yl)-2,5- diphenyltetrazolium bromide (MTT) hybrid assay. Cancer Res., 49: 4785-4790, 1989.
18. Hla, T., and Neilson, K. Human cyclooxygenase-2 cDNA. Proc. Natl. Acad. Sci. USA, 89: 7384-7388, 1992.
19. Horio, Y., Takahashi, T., Kuroishi, T., Hibi, K., Suyama, M., Niimi, T., Shimokata, K., Yamakawa, K., Nakamura, Y., Ueda, R., and Takahashi, T. Prognostic significance of p53 mutations and 3p deletions in primary resected non-small cell lung cancer. Cancer Res., 53: 1-4, 1993.
20. Suzuki, H., Takahashi, T., Kuroishi, T., Suyama, M., Ariyoshi, Y., Takahashi, T., and Ueda, R. p53 mutations in non-small cell lung cancer in Japan. Cancer Res., 52: 734-736, 1992.
21. Hockenbery, D., Nunez, G., Milliman, C., Schreiber, R. D., and Korsmeyer, S. J. Bcl-2 is an inner mitochondrial membrane protein that blocks programmed cell death. Nature (Lond.), 348: 334-336, 1990.
22. Warrington, S. J., Ravic, M., and Dawnay, A. Renal and general tolerability of repeated doses of nimesulide in normal subjects. Drugs, 46 (Suppl. 1): 263-269, 1993.
23. Liu, X. H., Yao, S., Kirschenbaum, A., and Levine, A. C. NS398, a selective cyclooxygenase-2 inhibitor, induces apoptosis and down-regulates bcl-2 expression in LNCaP cells. Cancer Res., 58: 4245-4249, 1998.
24. Steel, G. G., and Peckham, J. P. Exploitable mechanisms in combined radiotherapy-chemotherapy: the concept of additivity. Int. J. Radiat. Oncol. Biol. Phys., 5: 85-91, 1979.
25. Tsai, C. H., Gazdar, A. F., Venzon, D. J., Steinberg, S. M., Dedrick, R. L., Mulshine, J. L., and Kramer, B. S. Lack of in vitro synergy between etposide and cis-diammine-dichloroplatinum (II). Cancer Res., 49: 2390-2397, 1989.
26. Weichselbaum, R. R., Chen, G., and Hallahan, D. E. Biological and physical basis of radiation oncology. In: J. F. Holland, R. C. Bast, Jr., D. L. Morton, E. Frei III, D. W. Kufe, and R. R. Weichselbaum (eels.), Cancer Medicine, Ed. 4, pp. 697-726. Baltimore: Williams and Wilkins, 1997.
27. Soriano, A. F., Helfrich, B., Chan, D. C., Heasley, L. E., Bunn, P. A., Jr., and Chou, T. C. Synergistic effects of new chemopreventive agents and conventional cytotoxic agents against human lung cancer cell lines. Cancer Res., 59: 6178-6184, 1999.
28. Duffy, C. P., Elliott, C. J., O'Connor, R. A., Heenan, M. M., Coyle, S., Cleary, I. M., Kavanagh, K., Verhaegen, S., O'Loughlin, C. M., NicAmhlaoibh, R., and Clynes, M. Enhancement of chemotherapeutic drug toxicity to human tumour cells in vitro by a subset of non-steroidal anti-inflammatory drugs (NSAIDs). Eur. J. Cancer, 34: 1250-1259, 1998.
29. Milas, L., Kishi, K., Hunter, N., Mason, K., Masferrer, J. L., and Tofilon, P. J. Enhancement of tumor response to γ-radiation by an inhibitor of cyclooxygenase-2 enzyme. J. Natl. Cancer Inst., 91: 1501-1504, 1999.
30. Ginsberg, R. J., Vokes, E. E., and Raben, A. Non-small cell lung cancer. In: V. T. DeVita, Jr., S. Hellman, and S. A. Rosenberg (eds.), Cancer: Principles and Practice of Oncology, Ed. 5, pp. 849-911. Philadelphia: Lippincolt-Raven Publishers, 1997.
31. Sobue, T., Ajiki, W., Tsukuma, H., Oshima, A., Hanai, A., and Fujimoto, I. Trends of lung cancer incidence by histologic type: a population-based study in Osaka, Japan. Jpn. J. Cancer Res., 90: 6-15, 1999.